Recombinant NSD3 Monoclonal Antibody (AN302026L)
For research use only.
| Verified Samples | Verified Samples in WB: TH-29 (Low expression),?MOLT-4 |
| Dilution | WB 1:1000-1:3000 |
| Isotype | IgG, κ |
| Host | Rabbit |
| Reactivity | Human, |
| Applications | WB |
| Clonality | Monoclonal;Recombinant |
| Immunogen | Peptide. This information is proprietary to PTMab. |
| Abbre | NSD3 |
| Synonyms | NSD, WHSC1L, NSD3, KMT3F, KMT3G, WHISTLE, WHSC1L1, pp14328, DC28 |
| Swissprot | |
| Calculated MW | 162 kDa |
| Observed MW |
90 kDa
The actual band is not consistent with the expectation.
Western blotting is a method for detecting a certain protein in a complex sample based on the specific binding of antigen and antibody. Different proteins can be divided into bands based on different mobility rates. The mobility is affected by many factors, which may cause the observed band size to be inconsistent with the expected size. The common factors include: 1. Post-translational modifications: For example, modifications such as glycosylation, phosphorylation, methylation, and acetylation will increase the molecular weight of the protein. 2. Splicing variants: Different expression patterns of various mRNA splicing bodies may produce proteins of different sizes. 3. Post-translational cleavage: Many proteins are first synthesized into precursor proteins and then cleaved to form active forms, such as COL1A1. 4. Relative charge: the composition of amino acids (the proportion of charged amino acids and uncharged amino acids). 5. Formation of multimers: For example, in protein dimer, strong interactions between proteins can cause the bands to be larger. However, the use of reducing conditions can usually avoid the formation of multimers. If a protein in a sample has different modified forms at the same time, multiple bands may be detected on the membrane. |
| Cellular Localization | Nucleus |
| Concentration | 1 mg/mL |
| Buffer | PBS, 50% glycerol, 0.05% Proclin 300, 0.05% protein protectant. |
| Purification Method | Protein A purified |
| Research Areas | Epigenetics and Nuclear Signaling |
| Clone No. | A746 |
| Conjugation | Unconjugated |
| Storage | Store at -20°C Valid for 12 months. Avoid freeze / thaw cycles. |
| Shipping | Ice bag |
| background | Wolf-Hirschhorn syndrome candidate 1-like protein 1 (WHSC1L1), also known as histone-lysine N-methyltransferase NSD3, is a SET domaincontaining histone methyltransferase protein that methylates histone H3 on lysine 4 (H3K4me) and lysine 27 (H3K27me) (1). Methylation of histone H3 lysine 4 is associated with transcriptional activation, while methylation of histone H3 lysine 27 is associated with transcriptional repression. WHSC1L1 can function as an oncogene or a tumor suppressor protein, depending on cell context, and has been shown to regulate expression of a number of genes associated with cell cycle (2). Amplification and/or increased expression of WHSC1L1 in breast, lung, and liver cancer increases growth and survival, and is associated with poor prognosis (2-5). In addition, the NSD3 gene has been found fused with the nuclear pore complex protein NUP98 gene in acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), and fused with the NUT gene in NUT midline carcinomas (6-10). |
Other Clones
{{antibodyDetailsPage.numTotal}} Results
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
Other Formats
{{formatDetailsPage.numTotal}} Results
Unconjugated
-
{{item.title}}
Citations ({{item.publications_count}}) Manual MSDS
Cat.No.：{{item.cat}}
{{index}} {{goods_show_value}}
-
IF：{{item.impact}}
Journal：{{item.journal}} ({{item.year}})
DOI：{{item.doi}}Reactivity：{{item.species}}
Sample Type：{{item.organization}}
-
Q{{(FAQpage.currentPage - 1)*pageSize+index+1}}:{{item.name}}
